

## Special Issue

# Emerging and Reemerging Viral Infection, Immunopathogenesis and Diagnosis of Viral Infection, and Development of the Novel Antiviral Strategies

### Message from the Guest Editors

We are launching Special Issue on Emerging and re-emerging viral infections, immunopathogenesis and diagnosis of viral infections, and the development of novel antiviral strategies. In recent years, we have seen many emerging viruses, such as SARS-CoV-2, and re-emerging viruses, such as the monkeypox virus. Many virus outbreaks are ongoing in different parts of the world, causing morbidity and mortality: the COVID-19 pandemic, the monkeypox outbreak in nonendemic countries, the Dengue outbreak in Southeast Asia, CCHF, and the West Nile virus in Europe and America. Langya virus was detected in China, H1N1 and Nipha virus in India, a measles outbreak in Zimbabwe, and many more. Viral infection in any part of the world is a threat to global health and has the potential to cause epidemics and pandemics. Therefore, the diagnosis, detection, and management of viruses should be performed at their origin. With these issues in mind, in this Special Issue, we welcome original articles, review articles, perspectives, and interesting case series of emerging and reemerging viruses.

---

### Guest Editors

Dr. Ranjit Sah

Prof. Dr. Alfonso J. Rodriguez-Morales

Dr. Harapan Harapan

---

### Deadline for manuscript submissions

closed (30 July 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/144940](https://mdpi.com/si/144940)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).